PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer

References

• Cheng R, Chen Y, Zhou H, Wang B, Du Q, Chen Y. B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. Apmis. 2018;126:396–402.
   PubMed Web of Science ®Google Scholar
• Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78:237–247. doi:10.1016/j.jaad.2017.08.059
   PubMed Web of Science ®Google Scholar
• Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379:341–351. doi:10.1056/nejmoa1805131
   PubMed Web of Science ®Google Scholar
• Soura E, Gagari E, Stratigos A. Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available? Curr Opin Oncol. 2019;31:461–468. doi:10.1097/CCO.0000000000000566
   PubMed Web of Science ®Google Scholar
• Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. Pd-L1. J Clin Pathol. 2018;71:189–194. doi:10.1136/jclinpath-2017-204853
   PubMed Web of Science ®Google Scholar
• Dong H, Zhu G, Tamada K, Chen L. PD-L1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–1369. doi:10.1038/70932
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499. doi:10.1038/nri3862
   PubMed Web of Science ®Google Scholar
• Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261–268. doi:10.1038/85330
   PubMed Web of Science ®Google Scholar
• Wrona A. Role of immunotherapy in stage III nonsmall cell lung cancer. Curr Opin Oncol. 2019;31:18–23. doi:10.1097/CCO.0000000000000493
   PubMed Web of Science ®Google Scholar
• Karasar P, Esendagli G. T helper responses are maintained by basal-like breast cancer cells and confer to immune modulation via upregulation of PD-1 ligands. Breast Cancer Res Treat. 2014;145:605–614. doi:10.1007/s10549-014-2984-9
   PubMed Web of Science ®Google Scholar
• Wang L, Ma Q, Li D, et al. Indoleamine 2, 3-dioxygenase and PD-L1 expressions as prognostic and follow-up markers in human pancreatic carcinoma. Pathol Res Pract. 2018;214(9):1309–1314. doi:10.1016/j.prp.2018.02.016
   PubMed Web of Science ®Google Scholar
• Safaei HR, Rostamzadeh A, Rahmani O, et al. Prognostic investigations of PD-L1 and B7-H4 expression levels as independent predictor markers of renal cell carcinoma. Tumor Biol. 2016;37(6):7583–7587. doi:10.1007/s13277-015-4652-z
   PubMedGoogle Scholar
• Zhao L, Li C, Zhang R-L, et al. PD-L1 and B7-H4 expression in colorectal carcinoma: correlation with tumor FOXP3+ regulatory T-cell infiltration. Acta Histochem. 2014;116:1163–1168. doi:10.1016/j.acthis.2014.06.003
   PubMed Web of Science ®Google Scholar
• Geng Y, Wang H, Lu C, et al. Expression of costimulatory molecules PD-L1, B7-H4 and Foxp3+ Tregs in gastric cancer and its clinical significance. Int J Clin Oncol. 2015;20:273–281. doi:10.1007/s10147-014-0701-7
   PubMed Web of Science ®Google Scholar
• Tao J, Dai J, Hou S. Association between PD-L1 and cervical cancer: PD-L1 impairs the immune response in human cervical cancer cells. Exp Ther Med. 2017;14:4125–4133. doi:10.3892/etm.2017.5100
   PubMed Web of Science ®Google Scholar
• Barrios DM, Do MH, Phillips GS, et al. Immune checkpoint inhibitors to treat cutaneous malignancies. J Am Acad Dermatol. 2020;83:1239–1253. doi:10.1016/j.jaad.2020.03.131
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175. doi:10.1200/JCO.2009.26.7609
   PubMed Web of Science ®Google Scholar
• Khan M, Arooj S, Wang H, Cell-Based Immune NK. Checkpoint Inhibition. Front Immunol. 2020;11:548.
   PubMed Web of Science ®Google Scholar
• Haanen JBAG, Robert C. Immune Checkpoint Inhibitors. Prog Tumor Res. 2015;42:55–66.
   PubMed Web of Science ®Google Scholar
• Jiang X, Wang J, Deng X, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:1–17. doi:10.1186/s12943-018-0928-4
   PubMed Web of Science ®Google Scholar
• Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4:670–679. doi:10.1038/ni944
   PubMed Web of Science ®Google Scholar
• Kakavand H, Rawson RV, Pupo GM, et al. PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clin Cancer Res. 2017;23:6054–6061. doi:10.1158/1078-0432.CCR-16-1688
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Wei S, Dong H, et al. Blockade of PD-L1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med. 2003;9:562–567. doi:10.1038/nm863
   PubMed Web of Science ®Google Scholar
• Raez LE, Cassileth PA, Schlesselman JJ, et al. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:2800–2807. doi:10.1200/JCO.2004.10.197
   PubMed Web of Science ®Google Scholar
• Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with PD-L1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4. doi:10.1126/scitranslmed.3003689
   PubMed Web of Science ®Google Scholar
• Benson DM, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood. 2010;116:2286–2294. doi:10.1182/blood-2010-02-271874
   PubMed Web of Science ®Google Scholar
• Gadiot J, Hooijkaas AI, Kaiser ADM, et al. Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer. 2011;117(10):2192–2201. doi:10.1002/cncr.25747
   PubMed Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:1–15. doi:10.3389/fphar.2017.00561
   PubMed Web of Science ®Google Scholar
• Bagir EK, Acikalin A, Avci A, Gumurdulu D, Paydas S. PD-1 and PD-L1 expression in thymic epithelial tumours and non-neoplastic thymus. J Clin Pathol. 2018;71:637–641. doi:10.1136/jclinpath-2017-204788
   PubMed Web of Science ®Google Scholar
• Yao Y, Tao R, Wang X, et al. PD-L1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol. 2009;11:757–766. doi:10.1215/15228517-2009-014
   PubMed Web of Science ®Google Scholar